KMDAのPER（株価収益率）は？

KAMADA（KMDA）は現在PER 20.11倍で取引されています。

KMDAの配当利回りは？

KAMADAの配当利回りは3.57%です。

KMDAの品質スコア（Quality Score）は？

当社のAIはKMDAの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

KMDAは今が買い時ですか？

当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

KMDAはどのセクターに属しますか？

KAMADAはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます（NASDAQ市場）

KMDA (NASDAQ) 株価分析 | KAMADA

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

KMDA AI Analysis Summary

Our AI summary for KMDA: KAMADA (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 20.11, ROE of 7.85%, a dividend yield of 3.57%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

KMDA

KAMADA

US:NASDAQ STOCK Healthcare >> Drug Manufacturers - Specialty & Generic

USD 7.14

0.04 (0.56%) Day Change

Watchlist Portfolio Compare Chart

20.11

P/E

0.01

D/E

7.9%

ROE

5.3%

ROA

3.57%

Div Yield

-0.20

PEG

KAMADA
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 7.14 Price 0.04 (0.56%) Day Change	NEWS SCORE: N/A

KMDA, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROEの伸びが低い
平均ROEが低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Deepscope 分析

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	1448
Magic Formula Rank by ROE	1448
Magic Formula Rank by ROIC	1459
Price	7.14
PBV / Sector	1.58 / 3.22 GOOD
Earning Per Share	0.35

PE / Sector	20.11 / 29.79
PEG or PE/Growth / Sector	-0.20 / 0.13
Average 1M Daily Value	0.25 M GREAT
Average 1W Daily Value	0.33 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	11.21 / 15.21
NPM Average (%) / Sector	7.08 / -10.83
NPM Change Average (%) / Sector	-86.15 / 117.42
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	5.32 / 8.15
ROA Average (%) / Sector	3.23 / 2.87
ROA Change Average (%) / Sector	-80.20 / 112.70
ROE (%) / Sector	7.85 / -1.02
ROE Average (%) / Sector	4.60 / 8.35
ROE Change Average (%) / Sector	-63.50 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

62%

Dividend (%) / Sector	3.57 / 0.51 GOOD
Dividend Average (%) / Sector	3.24 / 3.06
Dividend Change Average (%) / Sector	22.32 / 13.64 GREAT

登録情報

Analyze Date	2026-08-01 08:00:05
Symbol	KMDA
Name	KAMADA
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	57.69 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	409.63 / 10,754.62

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 2 Holzman Street, Rehovot, Israel, 7670402

Phone: 972 8 940 6472

Website: https://www.kamada.com

Employees: 462

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.